Meeting
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab plus lenvatinib (P+L) versus alternative therapies in first-line (1L) advanced renal cell carcinoma (aRCC) by IMDC risk status: A network meta-analysis (NMA).
Authors
Pratik Rane
Merck & Co., Inc., North Wales, PA
Pratik Rane , Kevin Yan , Manuela Schmidinger , Avivit Peer , Eric Druyts , Joseph E. Burgents , Murali Sundaram
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 421)
DOI
10.1200/JCO.2024.42.4_suppl.421
Abstract #
421
Poster Bd #
H3
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab plus lenvatinib (P+L) versus alternate therapies in first-line (1L) for advanced renal cell carcinoma (aRCC): A network meta-analysis (NMA).
First Author: Kevin Yan
Poster
2024 ASCO Genitourinary Cancers Symposium
Network meta-analysis (NMA) to assess comparative efficacy of lenvatinib plus pembrolizumab compared with other first-line treatments for management of advanced renal cell carcinoma (aRCC).
First Author: Viktor Grünwald
Poster
2023 ASCO Genitourinary Cancers Symposium
CARINA interim analysis: A non-interventional study of real-world treatment sequencing and outcomes in patients with advanced renal cell carcinoma initiated on first-line checkpoint inhibitor-based combination therapy.
First Author: Paul D. Nathan
Poster
2022 ASCO Genitourinary Cancers Symposium
Network meta-analysis (NMA) of first-line advanced renal cell carcinoma (1L aRCC) treatments: Development of a decision algorithm for fractional polynomial (FP) model selection.
First Author: Bradley Alexander McGregor